About 3,288 results

ALLMedicine™ Acromegaly Center

Research & Reviews  1,133 results

International Multicenter Validation Study of the SAGIT ® Instrument in Acromegaly.
The Journal of Clinical Endocrinology and Metabolism; Giustina A, Bronstein MD et. al.

Jul 28th, 2021 - The SAGIT ® instrument (SAGIT) has been developed to enable accurate characterization of acromegaly disease activity. Evaluate the ability of SAGIT to discriminate between acromegaly disease control status. Multicenter, non-interventional, prospec...

T2-weighted magnetic resonance imaging as a novel predictor of surgical remission in ne...
Journal of Clinical Neuroscience : Official Journal of Th... Akkaya E, Akgun MY et. al.

Jul 20th, 2021 - Any preoperative diagnostic assessment that can predict the success of the operation in acromegaly will provide a positive impact on overall remission rates. The aim of this study is to reveal whether the signal intensity in T2-weighted Magnetic R...

Vertebral fractures occur despite control of acromegaly and are predicted by cortical v...
The Journal of Clinical Endocrinology and Metabolism; Kužma M, Vaňuga P et. al.

Jul 17th, 2021 - Recent studies suggest that cortical bone could also play a role in vertebral fracture (VF) development in acromegaly. Evaluate the occurrence of the VF and their relationship to DXA-derived bone parameters. A single-center two year prospective st...

Comparative effectiveness of endoscopic versus microscopic transsphenoidal surgery for ...
Clinical Neurology and Neurosurgery; Qiao N, Shen M et. al.

Jul 12th, 2021 - Previous studies failed to show the benefit of endoscopic surgery over microscopic surgery in terms of early endocrine remission. This study was to investigate whether early endocrine outcomes in patients with GH-secreting pituitary adenoma underw...

see more →

Guidelines  5 results

Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) ...
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Baroni MG, Giorgino F et. al.

Feb 26th, 2016 - Hyperglycemia is a common feature associated with states of increased growth hormone secretion and glucocorticoid levels. The purpose of these guidelines is to assist clinicians and other health care providers to take evidence-based therapeutic de...

Expert consensus document: A consensus on the medical treatment of acromegaly.
Nature Reviews. Endocrinology; Giustina A, Chanson P et. al.

Feb 26th, 2014 - In March 2013, the Acromegaly Consensus Group met to revise and update guidelines for the medical treatment of acromegaly. The meeting comprised experts skilled in the medical management of acromegaly. The group considered treatment goals covering...

American Association of Clinical Endocrinologists medical guidelines for clinical pract...
Endocrine Practice : Official Journal of the American Col... Katznelson L, Atkinson JL et. al.

Aug 24th, 2011 - American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.|2011|Katznelson L,Atkinson JL,Cook DM,Ezzat SZ,Hamrahian AH,|diagnosis,therapy,standards,trends,...

AME Position Statement on clinical management of acromegaly.
Journal of Endocrinological Investigation; Cozzi R, Baldelli R et. al.

Jan 23rd, 2010 - AME Position Statement on clinical management of acromegaly.|2010|Cozzi R,Baldelli R,Colao A,Lasio G,Zini M,|diagnosis,economics,epidemiology,therapy,

Guidelines for acromegaly management: an update.
The Journal of Clinical Endocrinology and Metabolism; Melmed S, Colao A et. al.

Feb 12th, 2009 - The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management. The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating...

see more →

Drugs  24 results see all →

Clinicaltrials.gov  74 results

Genetic Studies of Insulin and Diabetes

Apr 24th, 2020 - Insulin is the key hormone responsible for regulating the level of glucose in plasma. In several disease states (e.g., obesity, non-insulin-dependent diabetes mellitus, and acromegaly), the target cells are resistant to insulin action. The intramu...

The Treatment and Natural History of Acromegaly

Apr 8th, 2020 - The purpose of this study is to investigate the treatment and natural history of acromegaly. We have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases. We will continue to foll...

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Nov 22nd, 2019 - Six repeated applications of Lanreotide Autogel 120mg administered every 28, 42 or 56 days. For the first three injections, the interval depends on the Octreotide LAR dosage administered previously. The dose interval is titrated after injection 3 ...

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

Sep 12th, 2019 - This is a double blind, randomized study that assesses the efficacy and safety of octreotide capsules vs. placebo. Eligible acromegaly patients, treated with injectable somatostatin analogs, who are biochemically controlled and have prior evidence...

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Aug 5th, 2019 - The purpose of this study is to allow patients with acromegaly, or their partners, to learn how to successfully inject Somatuline Autogel at home. Ability to perform unsupervised injections whilst maintaining adequate disease control will be asses...

see more →

News  74 results

Fast Five Quiz: Test Your Knowledge of Acromegaly

Sep 16th, 2020 - Gigantism refers to abnormally high linear growth due to excessive action of insulin-like growth factor I (IGF-I) while the epiphyseal growth plates are open during childhood. Acromegaly is the same disorder of IGF-I excess but occurs after the gr...

Fast Five Quiz: Test Your Knowledge of Acromegaly

Sep 16th, 2020 - Gigantism is extremely rare, with approximately 100 reported cases to date. Acromegaly is more common than gigantism, with an incidence of 3-4 cases per million people per year and a prevalence of 60 cases per million population. A claims-based an...

Fast Five Quiz: Test Your Knowledge of Acromegaly

Sep 16th, 2020 - Causes of excess IGF-I action can be divided into the following three categories: Release of primary GH excess from the pituitary Increased GHRH secretion or hypothalamic dysregulation Hypothetically, the excessive production of IGF-binding protei...

Fast Five Quiz: Test Your Knowledge of Acromegaly

Sep 16th, 2020 - Answer 5/5 Which of the following is accurate regarding treatment of acromegaly? Your peers chose: Pharmacologic therapy is the first-line treatment for acromegaly 0% Radiation therapy is routinely indicated for most patients with acromegaly 0% Fo...

FDA Approves First Oral Somatostatin Analog for Acromegaly

Jun 29th, 2020 - The US Food and Drug Administration (FDA) has approved oral octreotide (Mycapssa, Chiasma) delayed-release capsules for the long-term maintenance treatment of patients with acromegaly who previously responded to and tolerated octreotide or lanreot...

see more →

Patient Education  5 results see all →